Under construction – not a live service
Sign in
Taking people in SingaporePhase 2

Testing MK-2214 in people with early Alzheimer's disease

Tests whether MK-2214 slows tau buildup in adults with early Alzheimer's disease.

Key facts

Who runs it
Merck Sharp & Dohme LLC
Where
Singapore, SingaporeSee the 2 sitesAlso in 10 other countries, 78 sites
Trial code
Registry title
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Status
Recruiting
Phase
Phase 2
People taking part
340 people, planned
Started
16 Jul 2025
Expected to end
30 Apr 2030
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • MK-2214
  • Placebo
Record updated
20 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 50 to 85 with mild cognitive impairment or mild dementia due to Alzheimer's disease. They need a study partner.

Age
50 Years to 85 Years
Sex
All sexes can join.
Disease stage
Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease.
Earlier treatment
If taking an approved Alzheimer's treatment for symptoms, the dose must have been stable for 3 months before screening.

Main reasons for not taking part

  • Known history of stroke or cerebrovascular disease
  • Another brain or nervous system disease, or structural brain disease
  • Seizures or epilepsy within 5 years before screening
  • Liver disease
  • Unwilling or unable to have a CT, PET, or MRI scan

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • The main inclusion criteria include but are not limited to the following:
  • Has mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD)
  • Has a designated study partner who can fulfill the requirements of this study
  • If on an approved AD therapy for symptomatic AD, the dosing regimen must have been stable for 3 months prior to screening

Who cannot take part

  • Has major medical illness or unstable medical condition within 3 months before screening
  • Has any immunological disease, which is not adequately controlled, or which requires treatment with biologics and/or immunosuppressants during the study
  • Has a known history of stroke or cerebrovascular disease
  • Has diagnosis of a clinically relevant central nervous system disease other than AD or other condition that negatively impacts cognition or cognitive status chronically
  • Has structural brain disease
  • Has a history of seizures or epilepsy within 5 years before screening
  • Has any other major central nervous system trauma, or infections that affect brain function
  • Has a bleeding disorder that is not under adequate control
  • Has a history of malignancy occurring within 5 years of screening
  • Has liver disease
  • Has a severe, acute, or chronic medical or psychiatric condition or laboratory abnormality
  • Has a risk factor for corrected QT interval (QTc) prolongation
  • The main exclusion criteria include but are not limited to the following:
  • Is unwilling or unable to undergo computed tomography (CT), positron emission tomography (PET), or magnetic resonance imaging (MRI) scan
  • Resides in a nursing home or assisted care facility with need for direct continuous medical care and nursing supervision

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 85 years old?

Where in Singapore

Also in 10 other countries, 78 sites

  • National Neuroscience Institute (Site 0101)Singapore, SingaporeContact: Study CoordinatorTaking people
  • Tan Tock Seng Hospital (Site 0102)Singapore, SingaporeContact: Study CoordinatorTaking people

About the trial

What the trial wants to find out

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD.

Read full original descriptionShow less

The goals of the study are to learn:

* If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it

The 2 groups in the trial

  • Base and Open-Label Extension Period: MK-2214Treatment being tested

    Participants will receive MK-2214 via intravenous (IV) infusion every 4 weeks (q4w) during the base period. After the completion of the base period participants have the option to continue receiving MK-2214 throughout the open-label extension period.

    Treatment: MK-2214

  • Base Period: PlaceboPlacebo, for comparison

    Participants will receive a placebo via IV infusion q4w during the base period.

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants With Early Alzheimer's Disease
Plain-language title
Testing MK-2214 in people with early Alzheimer's diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07033494, who can take part
Record updated
20 October 2026